RemedyMD launches first nationwide diabetes registry

RemedyMD (www.RemedyMD.com), the leading provider of Patient registry software, today announced the first nationwide Type 2 Diabetes registry to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: www.remedymd.com/cer100/type2.html

Aligned with the Institute of Medicine’s Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD’s type 2 diabetes registry includes long-term cost and compares medical management with education, support groups and behavior modification.

The type 2 diabetes registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

“Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies,” said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD’s new type 2 diabetes registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to type 2 diabetes research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of type2 diabetes researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: www.remedymd.com/cer100/type2.html.